問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
蘇穎文
下載
2024-11-20 - 2034-12-31
Condition/Disease
Test Drug
Participate Sites6Sites
Recruiting6Sites
2019-05-01 - 2026-12-31
2020-08-17 - 2023-12-12
2025-01-10 - 2031-05-31
2024-12-01 - 2027-12-31
Participate Sites5Sites
Recruiting5Sites
2023-03-27 - 2029-07-30
Not yet recruiting5Sites
Recruiting1Sites
2018-05-01 - 2023-09-30
TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer
Keytruda injection
Participate Sites15Sites
Terminated13Sites
Division of Thoracic Medicine
2019-10-01 - 2022-03-02
Advanced or Metastatic Biliary Tract Cancer
NUC-1031 for injection (Acelarin®)
全部
